This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday – Applied Optoelectronics (NASDAQ:AAOI), Arcutis Biotherapeutics (NASDAQ:ARQT)

Jul 25, 2025
this-palantir-technologies-analyst-begins-coverage-on-a-bullish-note;-here-are-top-5-initiations-for-friday-–-applied-optoelectronics-(nasdaq:aaoi),-arcutis-biotherapeutics-(nasdaq:arqt)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • Needham analyst Ryan Koontz initiated coverage on Applied Optoelectronics, Inc. AAOI with a Buy rating and announced a price target of $32. Applied Optoelectronics shares closed at $25.84 on Thursday. See how other analysts view this stock.
  • Goldman Sachs analyst Richard Law initiated coverage on Arcutis Biotherapeutics, Inc. ARQT with a Neutral rating and announced a price target of $18. Arcutis Biotherapeutics shares closed at $15.02 on Thursday. See how other analysts view this stock.
  • Mizuho analyst Steven Valiquette initiated coverage on Teladoc Health, Inc. TDOC with a Neutral rating and announced a price target of $10. Teladoc Health shares closed at $8.20 on Thursday. See how other analysts view this stock.
  • Piper Sandler analyst Brent Bracelin initiated coverage on Palantir Technologies Inc. PLTR with an Overweight rating and announced a price target of $170. Palantir Technologies shares closed at $154.86 on Thursday. See how other analysts view this stock.
  • Jefferies analyst Brian Tanquilut initiated coverage on Chemed Corporation CHE with a Hold rating and announced a price target of $500. Chemed shares closed at $463.02 on Thursday. See how other analysts view this stock.

Considering buying PLTR stock? Here’s what analysts think:

Trending Investment Opportunities

Read This Next:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.


Leave a comment